Andrew J. Bentall, M.B., Ch.B., M.D.

This is a randomized, multicenter, open-label, active control study to assess the safety and efficacy of tegoprubart compared with tacrolimus in the preservation of allograft function after kidney transplantation. Approximately 120 de novo kidney transplant recipients will receive rATG (Thymoglobulin®) induction, corticosteroid maintenance, mycophenolate, and will be randomized 1:1 to receive either tegoprubart 20 mg/kg intravenously (IV) every 21 days after an initial loading period or twice daily oral tacrolimus.

The purpose of this study is to evaluate how treatment and self-care after kidney transplant impacts people’s lives, relationships, and finances.